Clinical Trial Update: A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Global Phase III trial evaluating rilvegostomig or pembrolizumab monotherapy as first-line treatment for PD-L1-high metastatic non-small cell lung cancer, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Rilvegostomig (rilvegostomig)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small Cell Lung | Phase 3 | Status: RECRUITING